Completed OBSERVATIONAL NCT01362985

Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor

Monitoring of Plerixafor Off-Label Use in the European Group for Blood and Bone Marrow Transplantation (EBMT) Registry

Sponsor: European Society for Blood and Marrow Transplantation

Conditions Acute Leukemia Chronic Leukemia Lymphoma Myelodysplastic Syndrome Myeloproliferative Neoplasm Plasma Cell Disorders Solid Tumors

Updated 8 times since 2017 Last updated: Aug 12, 2015 Started: Jul 31, 2009 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Acute Leukemia and Chronic Leukemia, this trial is completed. The trial is conducted by European Society for Blood and Marrow Transplantation and has accumulated 8 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Nov 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Nov 2021 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: PHASE4 → None
Feb 2017 — Apr 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Society for Blood and Marrow Transplantation
Genzyme, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.